Просмотр статьи

<< Вернуться к списку статей журнала

Том 17 №4 2015 год - Нефрология и диализ

Клинические Практические Рекомендации KDIGO по Ведению Дислипидемии у Пациентов с Хронической Болезнью Почек


Марчелло Тонелли Кристоф Ваннер Алан Касс Амит Джарг Халвард Холдаас Алан Жардин Ликсин Джанг Флориан Кроненберг Рулан Парех Тецуи Шоши Роберт Уокер

Аннотация: Перевод с английского И.В. Островской и Е.В. Захаровой под общей редакцией Е.В. Захаровой Перевод выполнен по инициативе Российского Диализного Общества и одобрен KDIGO Все права принадлежат KDIGO Воспроизведение возможно только с разрешения РДО и KDIGO Предисловие к переводу на русский язык Клинических Практических Рекомендаций KDIGO по Ведению Дислипидемии у Больных с Хронической Болезнью Почек Глубокоуважаемые коллеги! В этом номере журнала Нефрология и Диализ мы продолжаем серию публикаций переводов на русский язык Клинических Практических Рекомендаций KDIGO, и предлагаем вашему вниманию перевод Рекомендаций по Ведению Дислипидемии у больных с Хронической Болезнью Почек. Как и предыдущие переводы, опубликованные в журнале Нефрология и Диализ, данный перевод осуществлен по инициативе Российского Диализного Общества с разрешения KDIGO. Руководство РДО и редколлегия журнала «Нефрология и Диализ» надеются, что публикуемый материал будет полезен вам в вашей работе. На сайте журнала «Нефрология и Диализ» и на сайте KDIGO вы можете также найти осуществленные по инициативе РДО переводы на русский язык Клинических Практических Рекомендаций KDIGO по МКН-ХБП, ОПП, Анемии у больных с ХБП, и Гломерулонефритам. С наилучшими пожеланиями от имени KDIGO и РДО, Е.В. Захарова Рабочая Группа Со-председатели Марчелло Тонелли, Университет Альберты, Эдмонтон, Канада Кристоф Ваннер, Университет Вюрцбурга, Вюрцбург, Германия Члены рабочей группы Алан Касс, Школа Исследований Здоровья, Дарвин, Австралия Амит Джарг, Лондонский Научный Центр Здоровья, Лондон, Канада Халвард Холдаас, Государственный Госпиталь, Осло, Норвегия Алан Жардин, Исследовательский Центр Сердечно-Сосудистых Заболеваний, Глазго, Великобритания Ликсин Джанг, Китайская Академия Медицинских Наук, Пекинский Объединенный Медицинский Колледж, Пекин, Китай Флориан Кроненберг, Медицинский Университет Инсбрука, Инсбрук, Австрия Рулан Парех, Детский Госпиталь, Торонто, Канада Тецуи Шоши, Университет Осака, Осака, Япония Роберт Уокер, Университет Отаго, Данедин, Новая Зеландия Группа обзора доказательств Центр Тафтса по разработке и внедрению рекомендаций по заболеваниям почек, Медицинский центр Тафтса, Бостон, Массачусетс, США: Ашиш Упадиаи, руководитель проекта Этан Балк, руководитель программы доказательной медицины Эми Эрли, координатор проекта Шана Хайнес, ассистент Дженни Ламон, менеджер Резюме Клинические Практические Рекомендации KDIGO 2013 предоставляют руководство по ведению и лечению дислипидемии у всех категорий пациентов с хронической болезнью почек (ХБП), включая не диализ-зависимых и диализ-зависимых больных и реципиентов почечного трансплантата. Настоящие Рекомендации содержат главы по оценке липидного статуса и лечению дислипидемии у взрослых и у детей. Созданию этих Рекомендаций предшествовал процесс тщательного поиска и детальной оценки доказательной базы. Подходы к лечению рассмотрены в каждой главе Рекомендаций и основаны на систематическом обзоре соответствующих клинических исследований. Оценка качества доказательной базы и сила рекомендаций соответствовала системе оценки GRADE. В Рекомендациях содержится также обсуждение имеющихся в настоящее время противоречий и ограничений доказательной базы, и предложения по проведению дальнейших исследований. Цитирование При цитировании этого документа необходимо использовать следующий формат: Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 259-305. Копирайт © 2013 принадлежит KDIGO. Все права защищены. Копирование для личного использования разрешено национальными законами об авторском праве. Право копирования по специальным ценам может быть предоставлено образовательным учреждениям, которые пожелают сделать копии для некоммерческого использования. Никакая часть этой публикации не может быть воспроизведена, дополнена или передана ни в какой форме и никаким способом, электронным или печатными, включая фотокопирование, запись или иную форму хранения информации и воспроизведения, без специального письменного разрешения KDIGO. Подробности получения разрешения на воспроизведение и перевод, и иную информацию по поводу политики KDIGO в отношении разрешений можно получить у Даниеллы Грин, директора по менеджменту, по адресу: danielle.green@kdigo.org Согласно законодательству, ни KDIGO, ни издание «Kidney International Supplements», ни Национальный Почечный Фонд (в прошлом являвшийся управляющим агентом KDIGO), ни авторы, ни иные лица, участвовавшие в разработке рекомендаций, ни редакторы, не несут обязательств компенсировать ущерб, нанесенный отдельным лицам или их собственности, и связанный с качеством произведенного продукта, по невниманию или иной причине, или при использовании любых методов, продуктов, инструкций или идей, содержащихся в данном материале.

Весь текст



Ключевые слова: cholesterol, chronic kidney disease, clinical practice guideline, dyslipidemia, evidence-based recommendation, KDIGO, systematic review, triglycerides, холестерин, хроническая болезнь почек, клинические практические рекомендации, дислипидемия, основанные на доказательствах рекомендации, KDIGO, систематический обзор, триглицериды

Список литературы:
  1. National Kidney Foundation. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41: S1-92.
  2. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49: S1-180.
  3. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998;32: S142-156.
  4. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995; 41: 1414-1420.
  5. Stein EA, Myers GL. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41: 1421-1426.
  6. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995; 41: 1427-1433.
  7. National Heart Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5): S213-256.
  8. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5: 2-5.
  9. Takahashi O, Glasziou PP, Perera R et al. Lipid re-screening: what is the best measure and interval? Heart 2010;96: 448-452.
  10. Glasziou PP, Irwig L, Heritier S et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008;148: 656-661.
  11. Jafri H, Karas RH, Alsheikh-Ali AA. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153: 800-808.
  12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
  13. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17: 2006-2016.
  14. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377: 2181-2192.
  15. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370: 1829-1839.
  16. Chiang CK, Ho TI, Hsu SP et al. Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purif 2005;23: 134-140.
  17. Coresh J, Longenecker JC, Miller III ER et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9: S24-S30.
  18. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61: 1887-1893.
  19. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15: 458-482.
  20. Krane V, Winkler K, Drechsler C et al. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am J Kidney Dis 2009; 54: 902-911.
  21. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291: 451-459.
  22. Tonelli M, Muntner P, Lloyd A et al. Association between LDL-C and Risk of Myocardial Infarction in CKD. J Am Soc Nephrol 2013; 24: 979-986.
  23. Grundy SM. Diabetes and coronary risk equivalency: what does it mean? Diabetes Care 2006;29: 457-460.
  24. Cooper A, Nherera L, Calvert N et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, 2008.
  25. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2): S1-113.
  26. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-1818.
  27. Tonelli M, Muntner P, Lloyd A et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380: 807-814.
  28. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339: 799-805.
  29. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
  30. Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44: 1587-1592.
  31. Latif F, Kleiman NS, Cohen DJ et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009;2: 37-45.
  32. Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-1454.
  33. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376: 1916-1922.
  34. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons With chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012;157: 263-275.
  35. Colhoun HM, Betteridge DJ, Durrington PN et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54: 810-819.
  36. Tonelli M, Jose P, Curhan G et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006;332: 1426.
  37. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110: 2809-2816.
  38. Wilson PW, D’Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-1847,
  39. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33: 1635-1701.
  40. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315.
  41. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93: 172-176.
  42. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336: 1475-1482.
  43. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353: 238-248.
  44. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360: 1395-1407.
  45. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons With chronic kidney disease: A systematic Review and meta-analysis. Ann Intern Med 2012;157: 251-262.
  46. Hou W, Lv J, Perkovic V et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013;34: 1807-1817.
  47. Marz W, Genser B, Drechsler C et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6: 1316-1325.
  48. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361: 2024-2031.
  49. Pilmore H, Dent H, Chang S et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89: 851-857.
  50. Saito Y, Goto Y, Dane A et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003;10: 329-336.
  51. Saito Y, Goto Y, Nakaya N et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis 1988; 72: 205-211.
  52. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368: 1155-1163.
  53. Nakamura H, Mizuno K, Ohashi Y et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206: 512-517.
  54. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32: S112-119.
  55. Srinivasan SR, Myers L, Berenson GS. Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. Pediatrics 2002;110: e29.
  56. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999;281: 727-735.
  57. Berenson GS, Srinivasan SR, Bao W et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338: 1650-1656.
  58. Magnussen CG, Raitakari OT, Thomson R et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 2008;117: 32-42.
  59. Schrott HG, Bucher KA, Clarke WR et al. The Muscatine hyperlipidemia family study program. Prog Clin Biol Res 1979;32: 619-646.
  60. Jarvisalo MJ, Jartti L, Nanto-Salonen K et al. Increased aortic intima- media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 2001;104: 2943-2947.
  61. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease;and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114: 2710-2738.
  62. Olson RE. Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr 2000; 47: 55-78.
  63. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002;14: 197-204.
  64. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007;22: 1095-1112.
  65. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Am J Kidney Dis 2009;53: S1-124.
  66. USRDS. US Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, 2004.
  67. Kwiterovich PO Jr, Barton BA, McMahon RP et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation 1997;96: 2526-2533.
  68. Niinikoski H, Koskinen P, Punnonen K et al. Intake and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol: the STRIP baby study. Special Turku Coronary Risk Factor Intervention Project for Babies. Am J Clin Nutr. 1997;66: 569-574.
  69. Niinikoski H, Lapinleimu H, Viikari J et al. Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. Pediatrics 1997;99: 687-694.
  70. Niinikoski H, Viikari J, Ronnemaa T et al. Regulation of growth of 7- to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial. Pediatrics 1997;100: 810-816.
  71. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996;10: 171-174.
  72. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P et al. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol 2009;24: 1205-1210.
  73. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997;130: 470-474.
  74. Yoshimura N, Oka T, Okamoto M et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992;53: 94-99.
  75. Avis HJ, Hutten BA, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55: 1121-1126.
  76. Clauss SB, Holmes KW, Hopkins P et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholes- terolemia. Pediatrics 2005; 116: 682-688.
  77. de Jongh S, Lilien MR, op’t Roodt J et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40: 2117-2121.
  78. de Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double- blind, placebo-controlled trial with simvastatin. Circulation 2002;106: 2231-2237.
  79. Knipscheer HC, Boelen CC, Kastelein JJ et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996;39: 867-871.
  80. Lambert M, Lupien PJ, Gagne C et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996;97: 619-628.
  81. McCrindle BW, Helden E, Cullen-Dean G et al. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002;51: 715-721.
  82. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143: 74-80.
  83. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116: 664-668.
  84. Stein EA, Illingworth DR, Kwiterovich PO Jr et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281: 137-144.
  85. van der Graaf A, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52: 1421-1429.
  86. van der Graaf A, Nierman MC, Firth JC et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Paediatr 2006;95: 1461-1466.
  87. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292: 331-337.
  88. Preiss D, Tikkanen MJ, Welsh P et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012;308: 804-811.
  89. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376: 1670-1681.
  90. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375: 1875-1884.
  91. Tonelli M, Collins D, Robins S et al. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004;66: 1123-1130.
  92. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45: 485-493.
  93. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
  94. Ting RD, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012;35: 218-225.
  95. Davis TM, Ting R, Best JD et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54: 280-290.
  96. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563-1574.
  97. Zhao YY, Weir MA, Manno M et al. New fibrate use and acute renal outcomes in elderly adults a population-based study. Ann Intern Med 2012;156: 560-569.
  98. Chen HH, Lin LH. Recurrent pancreatitis secondary to type V hyper- lipidemia: report of one case. Acta Paediatr Taiwan 2000;41: 276-278.
  99. Spratt P, Esmore D, Keogh A et al. Comparison of three immunosuppressive protocols in cardiac transplantation. Transplant Proc 1989;21: 2481-2483.
  100. Chicaud P, Demange J, Drouin P et al. [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. Presse Med 1984; 13: 417-419.
  101. Steinmetz J, Morin C, Panek E et al. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981;112: 43-53.
  102. Wheeler KA, West RJ, Lloyd JK et al. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985;60: 34-37.
  103. Cerkauskiene R, Kaminskas A, Kaltenis P et al. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome]. Medicina 2003;39(Suppl 1): 82-87.
  104. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U et al. Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. J Med Assoc Thai 1999;82(Suppl 1): S122-S128.
  105. Goren A, Stankiewicz H, Goldstein R et al. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics 1991;88: 265-268.
  106. Hogg RJ, Lee J, Nardelli N et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006;1: 467-474.
  107. Owens DK, Lohr KN, Atkins D et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions- agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010;63: 513-523.
  108. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328: 1490.
  109. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008;336: 1049-1051.
  110. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;70: 2058-2065.
  111. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12: 18-23.
  112. Shiffman RN, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493-498.
  113. Institute of Medicine. Finding What Works in Health Care: Standards for Systematic Reviews. The National Academies Press: Washington, DC, 2011.
  114. Institute of Medicine. Clinical Practice Guidelines We Can Trust. National Academies Press: Washington, DC, 2011.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи